Get started
Author

Shiva Baghaie

Deletion of ghrelin prevents aging‐associated obesity and muscle dysfunction without affecting longevity
2017 · Bobby Guillory, Ji‐an Chen, et al. · Aging Cell · 37
PDF
A Prediction Model to Help with Oncologic Mediastinal Evaluation for Radiation: HOMER
2019 · Gabriela Martinez-Zayas, Francisco A. Almeida, et al. · American Journal of Respiratory and Critical Care Medicine · 33
A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (Alliance A031701).
2022 · Gopa Iyer, Karla V. Ballman, et al. · Journal of Clinical Oncology · 30
Feasibility and Reliability of Home-based Spirometry Telemonitoring in Allogeneic Hematopoietic Cell Transplant Recipients
2020 · Ajay Sheshadri, Amin Alousi, et al. · Annals of the American Thoracic Society · 21
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001).
2022 · Shilpa Gupta, Karla V. Ballman, et al. · Journal of Clinical Oncology · 12
A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL/Alliance A031801).
2021 · Rana R. McKay, Heather Jacene, et al. · Journal of Clinical Oncology · 9
A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101).
2024 · Atish Dipankar Choudhury, Glenn Heller, et al. · Journal of Clinical Oncology · 8
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib (CABO) and avelumab (Av) vs Av after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).
2024 · Shilpa Gupta, Karla V. Ballman, et al. · Journal of Clinical Oncology · 2
PDF
ASPIRE: A randomized phase III trial of androgen deprivation therapy (ADT) plus apalutamide (A) with or without docetaxel (D) in metastatic castration-sensitive prostate cancer (mCSPC) stratified by tumor suppressor gene alterations (Alliance A032302).
2026 · Deepak Kilari, Karla V. Ballman, et al. · Journal of Clinical Oncology · 1
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).
2023 · Shilpa Gupta, Karla V. Ballman, et al. · Journal of Clinical Oncology · 1
Alliance A032002 (ART): Phase II randomized trial of atezolizumab versus atezolizumab and radiation therapy for platinum-ineligible/refractory metastatic urothelial cancer.
2023 · Himanshu Nagar, Karla V. Ballman, et al. · Journal of Clinical Oncology · 1
PDF
MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy (PBC) in patients (pts) with locally advanced/metastatic urothelial cancer (la/mUC; Alliance A032001).
2026 · Shilpa Gupta, Karla V. Ballman, et al. · Journal of Clinical Oncology
Prediction Model for Malignant N1, N2 or N3 Nodal Disease Relative to N0 in Patients with Non-Small Cell Lung Cancer
2019 · G. Martinez-Zayas, F.A. Almeida, et al.
Works count: 13
Citation count: 155
H-index: 7
I10-index: 5
Year
Topic
Type